These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 12123336

  • 21. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [Abstract] [Full Text] [Related]

  • 22. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
    Buchner A, Elsässer R, Bias P.
    Breast Cancer Res Treat; 2014 Nov; 148(1):107-16. PubMed ID: 25261291
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R.
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [Abstract] [Full Text] [Related]

  • 24. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
    Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C.
    J Pediatr Hematol Oncol; 2005 Aug; 27(8):449-51. PubMed ID: 16096530
    [Abstract] [Full Text] [Related]

  • 25. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
    Meza LA, Green MD, Hackett JR, Neumann TA, Holmes FA.
    Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389
    [Abstract] [Full Text] [Related]

  • 26. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J.
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [Abstract] [Full Text] [Related]

  • 27. Pegfilgrastim: the promise of pegylation fulfilled.
    Crawford J.
    Ann Oncol; 2003 Jan; 14(1):6-7. PubMed ID: 12488286
    [No Abstract] [Full Text] [Related]

  • 28. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 29. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M, Esteves S, André R, Isidoro M, Moreira A.
    Support Care Cancer; 2016 Feb 08; 24(2):597-603. PubMed ID: 26111956
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 08; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 31. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
    George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC.
    Leuk Lymphoma; 2003 Oct 08; 44(10):1691-6. PubMed ID: 14692520
    [Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
    Crawford J.
    Pharmacotherapy; 2003 Aug 08; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
    [Abstract] [Full Text] [Related]

  • 33. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K, Donskih R, Jones CM, Nixon A, Vidal MJ, Nakov R, Singh P, Schaffar G, Gascón P, Harbeck N.
    Oncologist; 2016 Jul 08; 21(7):789-94. PubMed ID: 27091420
    [Abstract] [Full Text] [Related]

  • 34. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ.
    Anticancer Drugs; 2013 Jul 08; 24(6):641-7. PubMed ID: 23571496
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
    Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilas G, Maniadakis N.
    Support Care Cancer; 2015 Jul 08; 23(7):2045-51. PubMed ID: 25524005
    [Abstract] [Full Text] [Related]

  • 37. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
    Sohn BS, Jeong JH, Ahn JH, Jung KH, Kim JE, Sohn JH, Koh SJ, Seo JH, Lee KS, Kim SB.
    Invest New Drugs; 2020 Jun 08; 38(3):866-873. PubMed ID: 31728715
    [Abstract] [Full Text] [Related]

  • 38. Pegfilgrastim for chemotherapy-induced neutropenia.
    Bedell C.
    Clin J Oncol Nurs; 2003 Jun 08; 7(1):55-6, 63-4. PubMed ID: 12629935
    [Abstract] [Full Text] [Related]

  • 39. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A.
    Leuk Lymphoma; 2006 Mar 08; 47(3):481-5. PubMed ID: 16396772
    [Abstract] [Full Text] [Related]

  • 40. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct 08; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.